Bahri Altay / Shutterstock-com
Patient choice is at the heart of plans in the UK to expedite access to pharma-branded medicines in the NHS, but how will innovator companies be affected? LSIPR reports.
In April, the UK government is expected to publish the Accelerated Access Review. The report is intended to suggest a method of speeding up patients’ access to the latest medicines developed by pharmaceutical companies in the current restricted financial climate at the National Health Service (NHS).
Tasked with this job is Sir Hugh Taylor, an experienced civil servant with a number of years behind him working in the Department of Health. Last October, he published an interim report, which has been welcomed by many in the pharma industry.
The interim report is 26 pages long and centres on five proposals. One of the main suggestions is an increased focus on patient choice. Taylor notes that patients are increasingly “taking advantage of innovation, particularly in the digital sphere, to manage their own care across a range of conditions”.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
National Health Service, NHS, patient, innovation,British Pharmaceutical Industry, pharmaceutical,
